popular semaglutide Type 2 Diabetes Drug Associated with Increased Risk of NAION Study raises red flags over

A center that is definitely on point on many levels

Flow of patients through the trial Perkovic et al , NEJM 2024 The randomized participants had a mean age of 66.6 years

Mochi Health Treatments Weight loss GLP-1/GIP injectables (tirzepatide: Zepbound/Mounjaro), GLP-1 injectables (semaglutide: Wegovy/Ozempic

Just medically guided, sustainable results

Though side effects may feel challenging initially, most patients find them manageable with proper support and careful adherence to management strategies

Comparing the GLP-1 experience with other well-studied medication classes provides useful context and additional management insights